Combined therapy of Sr-89 and zoledronic acid in patients with painful bone metastases (Articolo in rivista)

Type

• Articolo in rivista (Classe)
• Prodotto della ricerca (Classe)

Label

• Combined therapy of Sr-89 and zoledronic acid in patients with painful bone metastases (Articolo in rivista) (literal)

Anno

• 2006-01-01T00:00:00+01:00 (literal)

Alternative label

• Storto G, Klain M, Paone G, Liuzzi R, Molino L, Marinelli A, Soricelli A, Pace L, Salvatore M. (2006)
  Combined therapy of Sr-89 and zoledronic acid in patients with painful bone metastases
  in Bone (New York, NY)
  (literal)

Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#autori

• Storto G, Klain M, Paone G, Liuzzi R, Molino L, Marinelli A, Soricelli A, Pace L, Salvatore M. (literal)

Pagina inizio

• 35 (literal)

Pagina fine

• 41 (literal)

Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#numeroVolume

• 39 (literal)

Rivista

• Bone (Rivista)

Note

• ISI Web of Science (WOS) (literal)

Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#affiliazioni

• IBB CNR (literal)

Titolo

• Combined therapy of Sr-89 and zoledronic acid in patients with painful bone metastases (literal)

Abstract

• Purpose: We evaluated the pain response and daily discomfort in patients with painful bone metastases treated by merging Sr-89-chloride and zoledronic acid. The results were compared with those of patients who received 89Sr-chloride or zoledronic acid separately. Methods: 25 patients (12 women; mean age 65 +/- 13 years) chronically treated with zoledronic acid underwent bone pain palliation with 150 MBq of Sr-89-chloride at least 6 months later that bisphoshonate therapy started (group A). 13 patients (6 women; mean age 70 +/- 12 years) received Sr-89-chloride alone (group B) and 11 patients (5 women; mean age 69 +/- 12 years) were chronically treated and continued to receive only zoledronic acid therapy (group C), both constituted the control groups. Patients kept a daily pain diary assessing both their discomfort and the pain of specific sites by using a visual analog scale (VAS), rating from 0 (no discomfort-no pain) to 10 (worst discomfort-pain). These diaries were reviewed weekly for 2 months and three different physicians rated the pain response on a scale of -2 (considerable deterioration) to +2 (considerable improvement). Results: Baseline characteristics were similar in the three groups. The reduction of total discomfort and of bone pain in the group A was significantly greater as compared to group B (P < 0.01) and group C (P < 0.01). During the monitored period, a significant improvement of clinical conditions was observed in the group A, varying the rate from -1 to 1 as compared to both groups B and C in which the rate changed from -1 to 0. Conclusion: Our findings indicate that combined therapy of Sr-89-chloride and zoledronic acid in patients with painful bone metastases is more effective in treating pain and improving clinical conditions than Sr-89-chloride or zoledronic acid used separately (literal)

Prodotto di

• Imaging Morfo-funzionale Integrato delle Patologie del Distretto Toraco-addominale e Sviluppo di Sistemi Integrati di Gestione e Trasmissione di Dati (ME.P06.003.001) (Modulo)
• Institute of biostructure and bioimaging (IBB) (Istituto)

Autore CNR

• RAFFAELE LIUZZI (Unità di personale interno)
• MARCO SALVATORE (Persona)
• GIOVANNI STORTO (Unità di personale interno)

Incoming links:

Autore CNR di

• RAFFAELE LIUZZI (Unità di personale interno)
• MARCO SALVATORE (Persona)
• GIOVANNI STORTO (Unità di personale interno)

Prodotto

• Institute of biostructure and bioimaging (IBB) (Istituto)
• Imaging Morfo-funzionale Integrato delle Patologie del Distretto Toraco-addominale e Sviluppo di Sistemi Integrati di Gestione e Trasmissione di Dati (ME.P06.003.001) (Modulo)

Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#rivistaDi

• Bone (Rivista)